US Veterinary Monoclonal Antibodies Market (2025-2030)
The US Veterinary Monoclonal Antibodies Market was valued at $789.25 Million in 2025 and projected to reach to $1508.4 Million by 2030, representing a compound annual growth rate of 13.8%. The US veterinary monoclonal antibodies market is poised for sustained expansion through 2030, driven by rising pet healthcare spending, increasing prevalence of chronic animal diseases, and growing adoption of precision medicine in veterinary practice.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Veterinary Monoclonal Antibodies Market Trends and Insights
- This expansion reflects the US's leadership in advanced veterinary therapeutics and increasing adoption of targeted immunotherapy solutions for companion and production animals.
- The US market benefits from strong regulatory frameworks, high pet ownership rates, and significant investment in animal health innovation. Driving this 13.8% compound annual growth rate, the US market is characterized by rising demand for precision medicine in veterinary care, growing prevalence of chronic diseases in animals, and expanding applications of monoclonal antibodies across oncology, immunology, and infectious disease management.
- The US veterinary sector's emphasis on quality of life for animals and willingness to invest in advanced treatments positions the country as a key growth engine within North America. By 2030, the US is expected to solidify its position as a major market for veterinary monoclonal antibodies, driven by continued R&D investments, emerging therapeutic indications, and increasing collaboration between pharmaceutical companies and veterinary institutions across the country..
Key Market Statistics
- CAGR (2025-2030) 13.8% CAGR
- Market Size, 2025 ~USD 789.25 Million
- Forecast, 2030 ~USD 1508.4 Million
- Country US
US Veterinary Monoclonal Antibodies Market Overview
Market Valuation & Growth :
The US veterinary monoclonal antibodies market is valued at $789.25 million in 2025, with a robust CAGR of 13.8% projected through 2030, reaching $1,508.4 million. This growth outpaces the global average of 12.4%, positioning the US as a key market driver.
Regulatory Leadership :
The US benefits from FDA's established regulatory pathways for veterinary biologics, enabling faster approval of innovative monoclonal antibody therapeutics. This regulatory advantage attracts significant R&D investment and accelerates product commercialization compared to other regions.
Companion & Production Animal Focus :
US market growth is driven by increasing adoption of targeted immunotherapy for both companion animals (dogs, cats) and production animals (cattle, poultry). Pet owners' willingness to invest in advanced treatments and livestock productivity demands fuel dual-segment expansion.
Advanced Therapeutic Infrastructure :
The US maintains world-leading veterinary research institutions, biotech companies, and manufacturing capabilities. This ecosystem supports development of next-generation monoclonal antibody solutions and positions the country as an innovation hub for veterinary immunotherapeutics.
US Veterinary Monoclonal Antibodies Market Dynamics
- Companion animal owners increasingly seek advanced therapeutic options comparable to human medicine, while livestock producers invest in immunotherapy to enhance productivity and disease management.
- Technological advancements in antibody engineering and manufacturing will reduce costs and improve accessibility across veterinary practices. Key growth catalysts include expanding FDA approvals for novel monoclonal antibody products, integration of these therapies into standard veterinary protocols, and rising collaboration between pharmaceutical companies and veterinary institutions.
- The market will benefit from increased awareness among veterinarians and pet owners, coupled with improved reimbursement models.
- By 2030, monoclonal antibodies are expected to represent a significant portion of advanced veterinary therapeutics in the US, with applications spanning oncology, immunology, and infectious disease management..
Related Ecosystem
Animal Health
- Polymerase Chain Reaction (PCR) Tests
- Porcine
- Immunodiagnostics
- Lateral Flow Assays
- Microarrays
- Zoetis Inc.
- Patterson Companies, Inc.
- Virbac
- Elanco Animal Health Incorporated
- BOEHRINGER INGELHEIM GMBH
Key Takeaways
- The US veterinary monoclonal antibodies market is valued at $789.25 million in 2025 and will nearly double to $1,508.4 million by 2030.
- The US market is growing at a 13.8% CAGR, outpacing global growth and reflecting strong demand for advanced animal therapeutics.
- The US benefits from high pet ownership, robust regulatory infrastructure, and significant R&D investment in veterinary immunotherapy.
- By 2030, the US is positioned as a dominant market within North America, driven by expanding therapeutic applications and precision medicine adoption.
Veterinary Monoclonal Antibodies Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | BEDINVETMAB (LIBRELA) (Product) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 12.4% from 2025 to 2030 |
| Largest Segment | SUBCUTANEOUS ROUTE OF ADMINISTRATION (Route Of Administration) |
| Market Size Base Year (Billions) | ~USD 1.71 (2025) |
| Revenue Forecast (Billions) | ~USD 3.06 (2030) |
| Segments Covered | Animal Type, Product, Route Of Administration, Therapy Area, End User, Animal Type 2023-2030 |
US Veterinary Monoclonal Antibodies Market Report Segmentation
6 segment dimensions are covered across the global market.
By Animal Type
- Canines
- Felines
- Other Animal Types
- Other Animals
By Product
- Bedinvetmab (Librela)
- Canine Parvovirus Monoclonal Antibody (Cpma)
- Frunevetmab (Solensia)
- Gilvetmab
- Lokivetmab (Cytopoint)
- Other Products
By Route Of Administration
- Intravenous (Iv) Route Of Administration
- Intravenous Route Of Administration
- Oral Route Of Administration
- Subcutaneous (Sc) Route Of Administration
- Subcutaneous Route Of Administration
By Therapy Area
- Dermatology
- Infectious Diseases
- Oncology
- Other Therapy Areas
- Pain Management
By End User
- Other End Users
- Veterinary Clinics
- Veterinary Hospitals/ Specialty Centers
- Veterinary Hospitals/Specialty Clinics
- Veterinary Research & Academic Institutes
By Animal Type 2023-2030
- Canines
- Felines
- Other Animals
US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| OTHER END USERS | 64.68 | 71.11 | 78.27 | 86.21 | 104.74 | 115.54 | 127.64 | 10.3 |
| VETERINARY CLINICS | 247.65 | 283.38 | 324.72 | 372.28 | 490.08 | 562.75 | 647.1 | 14.8 |
| VETERINARY HOSPITALS/SPECIALTY CLINICS | 304.06 | 345.02 | 392.05 | 445.71 | 576.93 | 656.89 | 748.98 | 13.8 |
| VETERINARY RESEARCH & ACADEMIC INSTITUTES | 55.88 | 62.51 | 70.04 | 78.51 | 98.8 | 110.93 | 124.72 | 12.2 |
| TOTAL | 672.27 | 762.03 | 865.09 | 982.71 | 1270.55 | 1446.1 | 1648.44 | 13.8 |
Target Audience
- Veterinary Pharmaceutical Companies : Develop and commercialize monoclonal antibody products in the US market. Need detailed market sizing, competitive analysis, and regulatory pathways to inform R&D investment, product positioning, and go-to-market strategies for veterinary therapeutics.
- Investment & Private Equity Firms : Evaluate investment opportunities in US veterinary biotech and animal health companies. Require market growth projections, segment analysis, and competitive intelligence to assess portfolio companies, identify acquisition targets, and forecast financial returns.
- Veterinary Practice Networks & Hospitals : Integrate advanced monoclonal antibody therapies into clinical practice. Need market insights on approved products, clinical efficacy data, pricing trends, and reimbursement models to enhance service offerings and improve patient outcomes for companion and production animals.
- Contract Research & Manufacturing Organizations : Support development and production of veterinary monoclonal antibodies. Require market demand forecasts, regulatory requirements, and manufacturing trends to optimize capacity planning, identify client opportunities, and align service offerings with market growth.
- Government & Regulatory Agencies : Monitor veterinary therapeutic innovation and market trends. Need comprehensive market data and regulatory insights to inform policy decisions, approval processes, and oversight of veterinary monoclonal antibody products in the US market.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation ($789.25M in 2025) and verified CAGR of 13.8% through 2030. Validate investment decisions and business strategies with authoritative market sizing data specific to the US veterinary monoclonal antibodies sector.
- Competitive Landscape Intelligence : Understand the competitive positioning of US-based veterinary biotech companies, identify market leaders, and assess emerging players. Gain insights into product portfolios, regulatory approvals, and market share distribution across companion and production animal segments.
- Regulatory & Approval Pathway Insights : Navigate FDA approval processes and regulatory requirements specific to US veterinary monoclonal antibodies. Access detailed information on approval timelines, compliance frameworks, and strategic considerations for market entry and product commercialization.
- Segment-Specific Opportunity Analysis : Identify high-growth segments within the US market, including companion animal oncology, immunological disorders, and production animal health applications. Understand segment-specific drivers, unmet needs, and revenue potential for targeted business development.
- Strategic Partnership & Investment Guidance : Evaluate partnership opportunities with US veterinary institutions, biotech firms, and distribution networks. Identify acquisition targets, licensing opportunities, and investment hotspots to maximize market penetration and revenue growth in the expanding US market.
Frequently asked questions
What is the current size of the US veterinary monoclonal antibodies market?
The US veterinary monoclonal antibodies market is valued at $789.25 million in 2025 and is projected to reach $1,508.4 million by 2030.
What is the growth rate of the US veterinary monoclonal antibodies market?
The US market is expanding at a compound annual growth rate (CAGR) of 13.8% from 2025 to 2030.
What factors are driving growth in the US veterinary monoclonal antibodies market?
Key drivers include rising pet ownership, increasing prevalence of chronic animal diseases, demand for precision medicine in veterinary care, and expanding therapeutic applications in oncology and immunology.
Which animal segments are driving the US veterinary monoclonal antibodies market?
The US market is driven by both companion animals (dogs, cats) and production animals, with companion animal therapeutics representing a significant growth segment due to high owner spending on advanced treatments.
How does the US market compare to the global veterinary monoclonal antibodies market?
The US market is growing at 13.8% CAGR, which exceeds the global CAGR of 12.4%, positioning the US as a high-growth region within the global veterinary monoclonal antibodies landscape.
RESEARCH METHODOLOGY
This study involved the extensive use of both primary and secondary sources. The research process involved evaluating various factors affecting the industry to identify the segmentation, industry trends, key players, competitive landscape, market dynamics, and growth strategies.
Secondary Research
In the secondary research process, various secondary sources were referred to, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect valuable information for an extensive, technical, market-oriented, and commercial study of the veterinary monoclonal antibodies market. It was also used to obtain information about the key players, market classification & segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various primary sources from the supply and demand sides were interviewed to obtain critical qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, vice presidents, chairpersons, chief executive officers, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary monoclonal antibodies market. Primary sources from the demand side include professionals from veterinary hospitals and clinics, academic & research institutes, and pet owners.
Breakdown of primary interviews
Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the veterinary monoclonal antibodies market was determined after data triangulation from two approaches, as mentioned below. After each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
Veterinary monoclonal antibodies are laboratory-produced antibodies designed to target specific antigens in animals, offering precise treatment for conditions like atopic dermatitis, osteoarthritis, and infectious diseases. These species-specific biologics are engineered to work effectively in the immune systems of dogs, cats, or livestock. They represent a significant advancement over traditional drugs by providing targeted therapy with fewer side effects.
Stakeholders
- Veterinary monoclonal antibody manufacturers
- Animal healthcare product manufacturers
- Veterinary monoclonal antibody distributors and wholesalers
- Animal welfare associations
- Veterinary clinics and care centers
- Research and consulting firms
- Veterinary R&D organizations
- Contract research organizations
- Contract manufacturing organizations
- Venture capitalists
Report Objectives
- To define, describe, and forecast the veterinary monoclonal antibodies market by animal type, product, therapy area, route of administration, end user, and region
- To identify and analyze key drivers, restraints, opportunities, and challenges influencing market growth
- To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI, case study analysis, adjacent market analysis, unmet needs/end user expectations, and trends and disruptions impacting customer business in the market
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
- To strategically profile key players in this market and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market
Get the Full Veterinary Monoclonal Antibodies Market Report
Full forecast, segment splits, and company analysis for all Veterinary Monoclonal Antibodies Market.
- Canada Veterinary Monoclonal Antibodies Market
- Germany Veterinary Monoclonal Antibodies Market
- France Veterinary Monoclonal Antibodies Market
- UK Veterinary Monoclonal Antibodies Market
- Italy Veterinary Monoclonal Antibodies Market
- Spain Veterinary Monoclonal Antibodies Market
- Netherlands Veterinary Monoclonal Antibodies Market
- Japan Veterinary Monoclonal Antibodies Market
- China Veterinary Monoclonal Antibodies Market
- India Veterinary Monoclonal Antibodies Market
- Australia Veterinary Monoclonal Antibodies Market
- South Korea Veterinary Monoclonal Antibodies Market
- New Zealand Veterinary Monoclonal Antibodies Market
- Brazil Veterinary Monoclonal Antibodies Market
- Mexico Veterinary Monoclonal Antibodies Market
- Rest Of Europe Veterinary Monoclonal Antibodies Market
- Rest Of Asia Pacific Veterinary Monoclonal Antibodies Market
- Rest Of Latin America Veterinary Monoclonal Antibodies Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
